Search results 1-2 of 2 in Hepatitis C
Results
-
Phoenix/Scottsdale, Ariz.
View Summary
A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects
Location:
Phoenix/Scottsdale, Ariz.
Trial status:
Open for Enrollment
Why is this study being done?
Study Classification: Pharmacokinetics/ Pharmacodynamics
NCT ID:
NCT01309932
Who can I contact for additional information about this study?
Scottsdale: Hugo E Vargas, Site 040 480-342-1096
-
Rochester, Minn.
View Summary
A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in Which Peginterferon Lambda-1a (BMS-914143) Was Administered for the Treatment of Chronic Hepatitis C
Location:
Rochester, Minn.
Trial status:
Open for Enrollment
Why is this study being done?
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with BMS-914143 and achieved sustained virologic response
NCT ID:
NCT01525810
Who can I contact for additional information about this study?
Rochester: Michael Charlton, Site 012 507-284-2511